InnoGene Co Ltd

InnoGene maintains a strong liquidity position, with a current ratio of 14.18, indicating a significant buffer of current assets over current liabilities. The company holds KRW 1.58 billion in cash and equivalents, which is a substantial portion of its total assets of KRW 15.03 billion. The liquidity_fpt metric confirms that the firm is not under immediate liquidity pressure, with a low risk rating assigned in the risk assessment. Profitability metrics show a mixed picture. The company's return on equity (ROE) is 2.04%, and return on assets (ROA) is 1.92%, both below the typical thresholds for high-performing firms in the personal care industry. The net income of KRW 287.88 million is modest relative to the company's revenue of KRW 8.21 billion, suggesting that InnoGene is not currently generating strong returns on its equity base. Geographically and segment-wise, InnoGene's exposure is not disclosed in the input data. However, the company's primary business is in cosmetics and medical devices, with no indication of significant diversification across regions or product lines. The lack of segmental or geographic breakdown limits the ability to assess concentration risk in detail. The company's growth trajectory appears to be constrained. The outlook for the current fiscal year does not indicate a significant increase in revenue or profitability. The operating income of KRW 4.49 million is minimal compared to the gross profit of KRW 6.22 billion, suggesting that operational efficiency is a challenge. The free cash flow is negative at KRW -719.57 million, which could limit the company's ability to reinvest in growth opportunities. Risk factors for InnoGene are currently low, with no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio is 0.01, indicating a conservative capital structure with minimal leverage. However, the high price-to-earnings ratio of 63.06 suggests that the market may be pricing in future growth that has not yet materialized in the company's financials. Recent events and filings do not show any material changes in the company's operations or financial position. The absence of significant capital expenditures and the low level of long-term debt suggest a stable but potentially stagnant business model. The company's focus on skin regeneration and aging control products may offer long-term growth potential, but this is not yet reflected in its current financial performance.